B+
Bull case
15%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
YDES
Breeze AcquisitionFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
YD Bio has reported 17% FY2025 revenue growth, approximately $6.0 million of cash, expanded U.S. diagnostic access, and multiple planned regulatory milestones.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Coverage is low, analyst targets are unavailable, and the peer set is based mainly on same-sector market capitalization rather than direct operating comparability.
Momentum
100
Value
46
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.20 · Bull $3.50 · Bear $1.25Analysis 2026-07-23; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-23 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum100 · Δ7d -0.1
Value46 · Δ7d +0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Coverage is low, analyst targets are unavailable, and the peer set is based mainly on same-sector market capitalization rather than direct operating comparability.
- • FY2025 net loss and operating expenses were substantial relative to approximately $6.0 million of reported cash; cash runway and financing needs are not sufficiently established.
- • FY2025 net loss was approximately $8.3 million, operating expenses rose to about $5.4 million, and the company reported lower gross margin from a less favorable product mix.
Catalyst clock
2026-07-23
Post-earnings verification remains unresolved
Lead driver: Value · See fundamentals
Momentum
100
8% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+1.3
Value
46
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
0.0
Sentiment
0
45% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 99.5 / Value 46.5 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-23. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-07-23 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$350.67M
Beta
-
Shares Out
70.84M
P/E (TTM) · Derived
-39.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-15.14
Rev YoY
-
EPS YoY
-116.0%
Gross Margin
-
Op Margin
-
Net Debt
-$6M
Current Ratio
0.02
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data